Abstracts tagged "longitudinal studies"

Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
Abstract Number: 2469 • 2012 ACR/ARHP Annual Meeting
A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants
Robert M. Boudreau¹, David J. Hunter², Zhijie Wang³, Frank Roemer⁴, Felix Eckstein⁵, Michael J. Hannon³, Ali Guermazi⁶ and C. Kent Kwoh⁷, ¹Epidemiology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Radiology, Boston University School of Medicine, Boston, MA, ⁵Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ⁶Boston University, Boston, MA, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcomes, but has limitations as an endpoint in OA intervention trials. A definition…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting
The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study
Pedro Machado¹, Andrea Cortese¹, Jasper Morrow¹, Liz Dewar¹, Andy Hiscock¹, Adrian Miller¹, Stefen Brady², David Hilton-Jones², Matt Parton¹ and Michael G. Hanna¹, ¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ²Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting
Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?
C.J. Inman¹, Frederick Wolfe² and Kaleb Michaud³, ¹Pediatric Administration, University of Utah, Salt Lake City, UT, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
Abstract Number: 1587 • 2012 ACR/ARHP Annual Meeting
Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally
Malin Regardt¹, Marie-Louise Schult², Ingrid E. Lundberg³ and Elisabet MB Welin Henriksson⁴, ¹Department of Occupational Therapy, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Karolinska Institutet Rheum, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness. A recent study has shown that patients with PM and DM have reduced…
Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Jurgen Wollenhaupt¹, Joel C. Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Koshika Soma⁵, Lisy Wang⁴, Hiroyuki Nakamura⁶, Yoshihiro Komuro⁶, Chudi I. Nduaka⁴, David Gruben⁴, Birgitta Benda⁷, Samuel H. Zwillich⁵, Richard Riese⁴ and John D. Bradley⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Japan Inc., Tokyo, Japan, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
Abstract Number: 1125 • 2012 ACR/ARHP Annual Meeting
Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study
Jasmijn F. M. Holla¹, Marike van der Leeden¹, Leo D. Roorda², Martijn W. Heymans³, Sita M.A. Bierma-Zeinstra⁴, Maarten Boers⁵, Willem F. Lems⁶, Martijn P.M. Steultjens⁷ and Joost Dekker⁸, ¹Amsterdam Rehabilitation Research Center, Reade, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁴Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁵Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, ⁸Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Knee osteoarthritis (OA) is one of the leading causes of activity limitations among older adults. The course of activity limitations is highly variable; some…
Abstract Number: 1126 • 2012 ACR/ARHP Annual Meeting
Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up
Janet Wesseling¹, Sita M.A. Bierma-Zeinstra², Margreet Kloppenburg³, Johannes WJ Bijlsma⁴ and CHECK steering group⁵, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ³Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Leiden, Netherlands, ⁴Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht
Background/Purpose: Pain and disability related to osteoarthritis (OA) may generally be considered to be chronic, but it is known that its course can be very…
Abstract Number: 1110 • 2012 ACR/ARHP Annual Meeting
Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial
Emmanuel Maheu¹, Christian Cadet² and Francis Berenbaum¹, ¹Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ²Rheumatology, Paris, France
Background/Purpose: Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].